Alendronate is frequently used to treat postmenopausal osteoporosis; however, the effects of long-term treatment on BMD, bone turnover, and fracture risk remain poorly characterized. The Fracture ...

Prophylactic use of alendronate in elderly patients requiring oral prednisolone for whatever condition dramatically reduces the risk of hip fracture, at least in the short term, a new retrospective ...

Alendronate and risedronate are widely used to treat postmenopausal osteoporosis. A trial (FACT) assessed the efficacy of weekly doses of these agents over a 12-month period. Although both drugs ...

Bisphosphonate therapy is the current standard of care for the prevention and treatment of glucocorticoid-induced osteoporosis. Studies of anabolic therapy in patients who are receiving long-term ...

Romosozumab plus alendronate vs alendronate alone was associated with improved lumbar spine BMD among postmenopausal women with T2D and osteoporosis. Romosozumab followed by alendronate treatment ...

Giving 10mg per day of the bisphosphate drug alendronate to women after their menopause can help prevent loss of bone mass, reducing their risk of fractures, a Cochrane Review has found. This finding ...

Alendronate (Fosamax) reduces fracture rates among women with osteoporosis, usually defined as bone mineral density T-scores lower than -2.5. However, the benefit of alendronate in women with ...

Giving 10mg per day of the bisphosphate drug alendronate to women after their menopause can help prevent loss of bone mass, reducing their risk of fractures, a Cochrane Review has found. This finding ...

Compared with alendronate, teriparatide was associated with significantly greater pain reduction and better quality of life among postmenopausal women with osteoporosis. Teriparatide has a favorable ...

(HealthDay)—For females with osteoporosis, the rate of adjacent-level vertebral fractures is relatively low, with reduced odds with bisphosphonate therapy, according to a study published in the Dec. 1 ...

Since the use of parathyroid hormone as a treatment for osteoporosis is limited to two years or less, the question of whether antiresorptive therapy should follow parathyroid hormone therapy is ...

Alendronate (Restofos 70) is used to treat or prevent osteoporosis or bone thinning in men and post-menopausal women and Paget's disease or bone deformity. It is also recommended for patients taking ...